Anji Pharma
CompanyUnited States
Anji Pharma develops one asset, in phase 3 (Metformin DR in type 2 diabetes). Mostly small molecule acting on AMPK signalling, Insulin/IGF-1 signalling and mTOR signalling; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 2
- Trials
- 0
- Signals
Pipeline
1Delayed-release metformin targeting the lower bowel to activate AMPK and improve glycemic control.
Phase 3, Small molecule, AMPK signalling, Insulin/IGF-1 signalling, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms6
- Trials2
- Similar companies6